Compare Enbridge Inc (ENB) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs Moderna, Inc. — how do they compare? Enbridge Inc trades at $56.3 (market cap $121.39B), while Moderna, Inc. trades at $64.14 (market cap $27.09B). The key difference: Enbridge Inc is far larger — about 4.5× Moderna, Inc.'s market cap, and Enbridge Inc pays a 5.01% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| ENB | MRNA | |
|---|---|---|
Market Cap | $121.39B | $27.09B |
Sector | Energy | Health |
52-Week High | $58.04 | $81.80 |
52-Week Low | $44.59 | $22.36 |
Enterprise Value | $202.19B | $23.19B |
Dividend Yield | 5.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENB trades at $56.20, up 0.55% with a bullish technical outlook. Recent earnings show mixed results with Q1 2026 beating estimates but Q3 2025 missing. The company maintains strong cash flow from operations of $12.27B in 2025 and a 5.1% dividend yield. Revenue grew to $65.19B in 2025, with net income margin at 10%. Analyst consensus is evenly split between Buy and Hold ratings.
Outlook remains positive due to $28B in growth projects and stable dividends, but risks include high debt levels (debt-to-asset ratio 48.81% in 2025) and sensitivity to energy market volatility. The stock offers income appeal but faces execution risks on capital expenditures.
Moderna (MRNA) trades at $64.11, down 4.94% over 24 hours, with a bullish technical outlook but mixed fundamentals. The company reported a net loss of -$2.82B in 2025 despite beating EPS estimates in recent quarters. Recent news highlights progress in oncology trials and an EU RSV vaccine contract, fueling investor optimism about pipeline expansion beyond COVID-19 vaccines.
Outlook: Long-term growth depends on successful pipeline commercialization, but high cash burn and negative margins pose risks. Analyst consensus is cautious with a $49 price target, suggesting 23.6% downside. Investors should weigh clinical successes against persistent profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
